Reducing toxicity from targeted prostate cancer therapy
Minimizing salivary gland and renal toxicity arising from PSMA-targeted alpha therapy
['FUNDING_R01'] · SLOAN-KETTERING INST CAN RESEARCH · NIH-11061212
This study is looking at a new way to make a promising treatment for advanced prostate cancer safer by reducing side effects on the salivary glands and kidneys, so more patients can benefit from it without feeling as many negative effects.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SLOAN-KETTERING INST CAN RESEARCH (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11061212 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the safety of a promising treatment for metastatic castration-resistant prostate cancer (mCRPC) by minimizing harmful side effects on the salivary glands and kidneys. The approach involves using a combination of targeted alpha therapy with a specific agent, [225Ac]-PSMA-617, and a second compound, PSMA-11, to reduce toxicity while maintaining the effectiveness of the treatment. By adjusting the dosage and formulation, the researchers aim to enhance patient eligibility and treatment outcomes. This study will involve both laboratory experiments and clinical assessments to evaluate the safety and efficacy of the proposed method.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer who are seeking treatment options that minimize side effects.
Not a fit: Patients with early-stage prostate cancer or those who do not express prostate-specific membrane antigen (PSMA) may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer treatment options for patients with advanced prostate cancer, allowing more individuals to benefit from targeted therapies without severe side effects.
How similar studies have performed: Previous research has shown promising results with similar targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- SLOAN-KETTERING INST CAN RESEARCH — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PILLARSETTY, NAGAVARAKISHORE — SLOAN-KETTERING INST CAN RESEARCH
- Study coordinator: PILLARSETTY, NAGAVARAKISHORE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: androgen independent prostate cancer, androgen indifferent prostate cancer, androgen insensitive prostate cancer, androgen resistance in prostate cancer, androgen resistant prostate cancer